173 related articles for article (PubMed ID: 25703642)
1. Vemurafenib-induced hyperkeratosis of the areola treated with topical adapelene.
Martinez-Garcia E; Taibjee S; Koch D; Osborne R
Clin Exp Dermatol; 2016 Mar; 41(2):148-51. PubMed ID: 25703642
[TBL] [Abstract][Full Text] [Related]
2. Painful nipple hyperkeratosis secondary to vemurafenib.
Carr ES; Brown SC; Fiala KH
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28211633
[TBL] [Abstract][Full Text] [Related]
3. A case of vemurafenib-induced keratosis pilaris-like eruption.
Wang CM; Fleming KF; Hsu S
Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
5. Hyperkeratosis of the nipple and areola: 2 years of remission with low-dose acitretin and topical calcipotriol therapy.
Kartal Durmazlar SP; Eskioglu F; Bodur Z
J Dermatolog Treat; 2008; 19(6):337-40. PubMed ID: 18608736
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
7. Treatment of nevoid hyperkeratosis of the areola and nipple with topical tacalcitol: A case report.
Cinotti E; Provvidenziale L; Miracco C; Rubegni P
Dermatol Ther; 2018 Jul; 31(4):e12602. PubMed ID: 29624812
[No Abstract] [Full Text] [Related]
8. Vemurafenib-induced pityriasis amiantacea: a case report.
Bilgiç Ö
Cutan Ocul Toxicol; 2016 Dec; 35(4):329-31. PubMed ID: 26513697
[TBL] [Abstract][Full Text] [Related]
9. [Unilateral nevoid hyperkeratosis of the nipple and areola treated with topical calcitriol].
Guevara-Gutiérrez E; Tarango-Martínez VM; Sandoval-Tress C; Hernández-Torres M
Actas Dermosifiliogr; 2008; 99(6):500-1. PubMed ID: 18558069
[No Abstract] [Full Text] [Related]
10. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
Braunstein I; Gangadhar TC; Elenitsas R; Chu EY
J Cutan Pathol; 2014 Jun; 41(6):539-43. PubMed ID: 24517243
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
12. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.
Choe CH; McArthur GA; Caro I; Kempen JH; Amaravadi RK
Am J Ophthalmol; 2014 Oct; 158(4):831-837.e2. PubMed ID: 25036880
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
[TBL] [Abstract][Full Text] [Related]
14. Vemurafenib-induced eccrine squamous syringometaplasia.
Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
[TBL] [Abstract][Full Text] [Related]
15. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma.
Boyd KP; Vincent B; Andea A; Conry RM; Hughey LC
J Am Acad Dermatol; 2012 Dec; 67(6):1375-9. PubMed ID: 22940405
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature.
Vázquez-Osorio I; Sánchez-Aguilar MD; García-Rodiño S; Suárez-Peñaranda JM; Aliste C; Vázquez-Veiga H
Am J Dermatopathol; 2016 Jul; 38(7):e93-6. PubMed ID: 26959695
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
[TBL] [Abstract][Full Text] [Related]
18. Nevoid hyperkeratosis of the nipple and areola: treatment with topical retinoic acid.
Okan G; Baykal C
J Eur Acad Dermatol Venereol; 1999 Nov; 13(3):218-20. PubMed ID: 10642060
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
20. Early-Onset Vemurafenib-Induced DRESS Syndrome.
Munch M; Peuvrel L; Brocard A; Saint Jean M; Khammari A; Dreno B; Quereux G
Dermatology; 2016; 232(1):126-8. PubMed ID: 26418832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]